LySeqST:用于弥漫性大B细胞淋巴瘤稳健基因组分类的靶向测序检测
弥漫性大B细胞淋巴瘤(DLBCL)具有生物学异质性,LymphGen和DLBclass两种基因组分类系统可重复地将肿瘤分为具有预后相关性的亚型。本研究设计并验证了针对LymphGen分类所需基因组特征的靶向测序面板LySeqST,并与全外显子测序(WES)数据进行比较。结果表明LySeqST能准确使用LymphGen和DLBclass对DLBCL肿瘤进行分类,并在人群队列中验证了LymphGen亚型的预后相关性,仅表达暗区基因表达特征的肿瘤与较差结局一致相关。
要点
- LySeqST靶向测序面板可准确进行DLBCL的LymphGen和DLBclass基因组分类。
- 在真实世界队列中验证了LymphGen亚型的预后相关性。
- 仅暗区基因表达特征阳性的肿瘤与较差结局一致相关。
核心结论
- LySeqST可用于DLBCL的准确基因组分类。
研究设计与样本
- 设计并验证了捕获LymphGen分类所需基因组特征的靶向测序面板LySeqST。
- 进行了计算机理论验证和真实世界验证,与WES数据比较。
- 在未选择的人群队列中确定了LymphGen亚型的真实世界比例并验证其预后相关性。
主要发现
- LySeqST能准确使用LymphGen和DLBclass对DLBCL肿瘤进行分类。
- 在人群队列中验证了LymphGen亚型的预后相关性。
- 仅表达暗区基因表达特征的肿瘤与较差结局一致相关。
临床怎么用
- LySeqST可用于DLBCL的基因组分类,降低测序、数据存储和处理成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diffuse large B-cell lymphoma (DLBCL) is a biologically heterogeneous disease. Two genomic classification systems, LymphGen and DLBclass, are capable of reproducibly classifying single tumors into subtypes with prognostic relevance in the context of standard-of-care R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemoimmunotherapy. Preliminary data from subgroup analyses of clinical trials suggest that the distinct biological features are targetable with drugs that exploit subtype-specific vulnerabilities, and large clinical trials are being designed to test this hypothesis. Although whole-exome sequencing (WES) remains the gold standard for each of these classification systems, smaller targeted sequencing panels reduce costs associated with sequencing, data storage, and processing. Here, we describe the design and validation of a targeted sequencing panel (LySeqST) that captures the genomic features required specifically for LymphGen classification. We perform in silico theoretical and real-world validation vs WES data and demonstrate that LySeqST can be used to accurately classify DLBCL tumors using both LymphGen and DLBclass. In an unselected population-based cohort, we determine the real-world proportions and validate the prognostic relevance of LymphGen subtypes, confirming that only tumors expressing the dark zone gene expression signature are consistently associated with inferior outcomes. Our results support the use of LySeqST for accurate genomic classification of DLBCL.
引用
- Hilton LK, Gillis S, Y-Moayyed F, et al. LySeqST: a targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma. Blood Adv. 2026. PMID: 41985007. doi:10.1182/bloodadvances.2026020105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。